Sign in

Francesco Bertoni

@frbertoni.bsky.social
124 followers 190 following 65 posts

Institute of Oncology Research. President, ICML Local Organizing Committee. USI. Personal opinions only. #lymsm #lymphoma

PostsRepliesMedia
Reposted by Francesco Bertoni
American Association for Cancer Research (AACR) @theaacr.bsky.social · 13/05/2026
Degraders in Lymphoma: Shannon Buckley, Francesco Bertoni, and Justin Taylor will address this topic in a plenary session at the AACR Conference on Advances in Malignant Lymphoma (June 24-27; Philadelphia). Learn more: buff.ly/XH3lbfr #AACRlymphoma26 @frbertoni.bsky.social
023
Francesco Bertoni @frbertoni.bsky.social · 14/05/2026
Further exploring the role of ETS factors in lymphomas and how they can be targeted, a new paper by Filippo Spriano on mechanisms of resistance to TK-216 is now out. Thanks to all the collaborators. @usi.ch @iorbellinzona.bsky.social @sib.swiss doi.org/10.1002/cam4...
000
Francesco Bertoni @frbertoni.bsky.social · 27/11/2025
Our work on dual BTK and BCL2 inhibition in marginal zone lymphoma, using the new BTK degrader BGB-16673 and the BCL2 inhibitor sonrotoclax, is now available on @biorxivpreprint.bsky.social @iorbellinzona.bsky.social @usi.ch www.biorxiv.org/content/10.1...
biorxiv.org
Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax
Background: BTK and BCL2 represent key therapeutic targets in B-cell lymphomas, including marginal zone lymphoma (MZL). Here, we evaluated the novel BTK degrader BGB-16673, and the second-generation B...
020
Reposted by Francesco Bertoni
Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · 06/11/2025
#IORnews 🌊 Researchers from the IOR and the University of Galway in Ireland have identified a new natural compound from Irish marine life showing strong potential against an aggressive, hard-to-treat form of blood cancer. Learn more: ior.usi.ch/events-news/...
011
Reposted by Francesco Bertoni
International Conference on Malignant Lymphoma @icmlugano.bsky.social · 30/10/2025
Yesterday we had our first 19-ICML Local Organising Committee meeting — the behind-the-scenes work for the next edition has officially begun! 💥 @frbertoni.bsky.social #19ICML #ICML #lymphoma #CLL #myeloma #lymssm
021
Francesco Bertoni @frbertoni.bsky.social · 25/10/2025
Here are the 4 abstracts exploring novel therapeutics for patients with marginal zone lymphomas we're presenting at the #Targets25: -Epigenetic vulnerabilities in marginal zone lymphoma doi.org/10.1158/1535... @iorbellinzona.bsky.social @usi.ch
doi.org
Abstract C027: Epigenetic vulnerabilities in marginal zone lymphoma
AbstractBackground.. Alterations in chromatin-associated proteins contribute to the rewiring of transcriptional networks, promoting lymphomagenesis, disease progression, and resistance to therapies. T...
310
Reposted by Francesco Bertoni
Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · 16/10/2025
#IORnews An international study conducted by the IOR Experimental Hematology Laboratory, led by Prof. Davide Rossi, offers a new perspective on the genetics of classical Hodgkin lymphoma. Learn more: ior.usi.ch/events-news/...
011
Francesco Bertoni @frbertoni.bsky.social · 08/10/2025
Our letter by Nicolas Munz on in vitro lymphoma models for polatuzumab vedotin is now online in the British Journal of Haematology. Thanks to everybody at @iorbellinzona.bsky.social @usi.ch @snsf.ch onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Polatuzumab vedotin and CD79B: A study of efficacy in R‐CHOP‐resistant diffuse large B‐cell lymphoma
Click on the article title to read more.
010
Francesco Bertoni @frbertoni.bsky.social · 02/10/2025
The review article, written in collaboration with Camille Laurent, on the biology of marginal zone lymphomas is now published in Blood. @iorbellinzona.bsky.social @usi.ch Università della Svizzera italiana @snsf.ch doi.org/10.1182/bloo...
doi.org
The Biology of MZL subtypes: Challenge and Relevance of Classification
Marginal zone lymphomas (MZLs) are a heterogeneous group of low-grade B-cell neoplasms classified into different entities by the current lymphoma classific
020
Francesco Bertoni @frbertoni.bsky.social · 23/09/2025
“Recent Advances in Treating Diffuse Large B-Cell Lymphoma “ by Jim Armitage ascopost.com/issues/june-...
ascopost.com
Recent Advances in Treating Diffuse Large B-Cell Lymphoma
The disease we now call diffuse large B-cell lymphoma (DLBCL) has gone by the names of reticulum cell sarcoma, diffuse histiocytic lymphoma, and diffuse large cell lymphoma and included both lymphomas...
000
Francesco Bertoni @frbertoni.bsky.social · 21/09/2025
A work, by Filippo Spriano in our lab, exploring the mechanisms of resistance to TK216, a molecule that targets ETS factors, is now available in bioRxiv www.biorxiv.org/content/10.1...
biorxiv.org
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implica...
010
Francesco Bertoni @frbertoni.bsky.social · 19/09/2025
Our collaborative work with Sebastian Patzke and Jostein Dahle on the CD37 targetting radioimmunoconjugated antibody 177Lu-lilotomab satetraxetan (Betalutin) is out in the British Journal of Haematology. onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
000
Francesco Bertoni @frbertoni.bsky.social · 18/09/2025
Thanks to a collaboration with Francesco Buonocore and Maria Luisa Mangoni, we explored antimicrobial peptides (AMPs) in marginal zone lymphomas. The initial work by Filippo Spriano and others at the @iorbellinzona.bsky.social, is now available. @usi.ch www.biorxiv.org/content/10.1...
biorxiv.org
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted Therapies
Marginal zone lymphoma (MZL) is an indolent yet incurable B-cell malignancy in which targeted agents such as BTK and PI3K inhibitors frequently fail due to resistance or toxicity. Antimicrobial peptid...
040
Francesco Bertoni @frbertoni.bsky.social · 13/09/2025
A screening of the Irish marine biorepository identified a new bryostatin analog active in lymphomas. Nice collaboration with Olivier Thomas, his team, Filippo Spriano and other members of our @iorbellinzona.bsky.social lab. @usi.ch @sib.swiss chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/...
chemistry-europe.onlinelibrary.wiley.com
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B‐Cells Diffuse Large B‐Cell Lymphoma
Bryostatin analogs are found to be accumulated in the nudibranch Antiopella cristata collected in Irish waters. These are found to be potent inhibitors of activated B-cells diffuse large B-cell lymph....
030
Francesco Bertoni @frbertoni.bsky.social · 12/09/2025
Registrations are open for the next LyFE - Lymphoma Forum of Excellence «What's new in lymphoid neoplasias?», Bellinzona, Switzerland, February 2026 www.lymphomaforum.ch
lymphomaforum.ch
Home
000
Reposted by Francesco Bertoni
Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · 09/09/2025
#IORnews A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL. Learn more: tinyurl.com/ytybcbr8
021
Francesco Bertoni @frbertoni.bsky.social · 29/08/2025
Project Hail Mary by Andy Weir: a very nice reading! en.wikipedia.org/wiki/Project...
en.wikipedia.org
Project Hail Mary - Wikipedia
010
Francesco Bertoni @frbertoni.bsky.social · 07/08/2025
Elliott Smith - www.udiscovermusic.com/stories/best...
udiscovermusic.com
Best Elliott Smith Songs: 20 Essential Tracks
The best Elliott Smith songs reflect his ability to wring beauty out of life’s traumas. His prolific output still endures.
020
Reposted by Francesco Bertoni
ESMO - European Society for Medical Oncology @myesmo.bsky.social · 05/08/2025
📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx. #DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines 🔗 buff.ly/2ZYJc2c
062
Francesco Bertoni @frbertoni.bsky.social · 05/08/2025
new ESMO Lymphoma Clinical Practice Guideline for diagnosis, treatment and follow-up www.esmo.org/guidelines/e...
esmo.org
030
Reposted by Francesco Bertoni
Pedro Friedmann Angeli @angelifriedmann.bsky.social · 04/08/2025
A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience. If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome. pls share 🙏
055
Reposted by Francesco Bertoni
TingTing Zhang @tingtingzhang.bsky.social · 03/08/2025
Here is a curated list of #patienteducation resources in Simplified or Traditional #Chinese on #health- or #cancer- related topics available from US, UK, EU, Australia, Singapore, Hong Kong, Taiwan, and India. We are curating support groups in US - input needed blogs.hear2care.org/patientresou...
blogs.hear2care.org
中文漢語醫患資訊 – blogs.hear2care.org
033
Francesco Bertoni @frbertoni.bsky.social · 02/08/2025
“The Best Song From Every David #Bowie Album” by Ultimate Classic Rock: I largely agree but I would have chosen differently from some album. Difficult sometime to select only one song. Bowie is still the best one. ultimateclassicrock.com/david-bowie-...
ultimateclassicrock.com
David Bowie's Best Song From Each of His Albums
David Bowie's career reflects a rich evolution in music and persona, showcasing his vast influence across genres from rock to jazz.
020
Francesco Bertoni @frbertoni.bsky.social · 27/07/2025
Sonic Youth’s Daydream Nation amazed when they came out and I still listen to it. Wonderful album and band. www.udiscovermusic.com/stories/soni...
udiscovermusic.com
The Best Sonic Youth Songs: Alternative Classics
Such is the consistency and variety of their extensive catalogue, it's almost impossible to make a definitive best Sonic Youth songs list.
010
Francesco Bertoni @frbertoni.bsky.social · 24/07/2025
Slash’s 10 greatest riffs ever faroutmagazine.co.uk/slash-10-gre...
faroutmagazine.co.uk
The 10 greatest riffs of Slash's life
Slash is one of the most exciting and versatile guitarists in the world, and these top ten riffs prove exactly why that's the case.
010
Francesco Bertoni @frbertoni.bsky.social · 21/07/2025
Circulating miRNA in lymphomas. The work by Giulia Regazzo from Maria Giulio Rizzo’s group in Rome is out in the BJH. Glad to have contributed. @iorbellinzona.bsky.social @usi.ch onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
010
Francesco Bertoni @frbertoni.bsky.social · 21/07/2025
faroutmagazine.co.uk/jimi-hendrix...
faroutmagazine.co.uk
The Jimi Hendrix song that perfected the wah-wah pedal
A look at the wah-wah pedal, its history and how Jimi Hendrix perfected its use in one of his best-known and best-loved songs.
020
Francesco Bertoni @frbertoni.bsky.social · 15/07/2025
Our very interesting work on CXCR4 inhibition to increase the activity of therapies in B-cell lymphomas is now available in bioRxiv. Thanks to Laura Barnabei, Alberto Arribas, and all the contributors. @iorbellinzona.bsky.social @sib.swiss @usi.ch www.biorxiv.org/content/10.1...
biorxiv.org
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various ...
000
Reposted by Francesco Bertoni
Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · 05/07/2025
Registration is open for the International Prostate Cancer Symposium (IPCS) 28–29 April 2026 – Lugano, Switzerland Held just before APCCC 2026, IPCS is your chance to explore next-gen treatments & breakthrough research in prostate cancer care. 🔗Register now: apccc.org
001
Reposted by Francesco Bertoni
Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · 04/07/2025
#IORjobs IOR invites applications from outstanding candidates interested in applying for the SNSF Ambizione and Marie Skłodowska-Curie Actions (MSCA) and EMBO fellowships. ⏳ IOR internal deadline: 3 August 2025 ➡️ Details & application procedure: shorturl.at/caVdu
011
Francesco Bertoni @frbertoni.bsky.social · 04/07/2025
“The combination of glofitamab with R-CHOP or Pola-R-CHP is deliverable and results in high rates of durable response in this population of younger patients with high-burden supporting its ongoing exploration as a [first-line] treatment “ ascopubs.org/doi/10.1200/... ascopost.com/news/july-20...
ascopubs.org
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
PURPOSEImproved outcomes are needed for patients with high-risk (HR) large B-cell lymphoma (LBCL) who have <50% chance of cure with first-line (1L) R-CHOP chemotherapy. Patients with high burden or...
010
Francesco Bertoni @frbertoni.bsky.social · 01/07/2025
"Despite limitations of retrospective design and heterogeneity across BTKi agents, these results suggest that BTKi maintenance may redefine long-term management in PCNSL. " www.rarediseaseadvisor.com/news/btk-inh...
rarediseaseadvisor.com
BTK Inhibitors Extend Survival in Newly Diagnosed PCNSL
Maintenance with a BTK inhibitor yielded significantly longer PFS than lenalidomide in newly diagnosed PCNSL.
000
Francesco Bertoni @frbertoni.bsky.social · 30/06/2025
Very glad to be part of the faculty on the new ESO Comprehensive Online Course on Oncology Research and Clinical Trials. www.e-eso.net/courses/25RCT
e-eso.net
Comprehensive Online Course on Oncology Research and Clinical Trials
Comprehensive Online Course on Oncology Research and Clinical Trials FROM 19 September 2025
000
Francesco Bertoni @frbertoni.bsky.social · 20/06/2025
"T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma" by Gloria Iacoboni @icmlugano.bsky.social onlinelibrary.wiley.com/doi/abs/10.1...
onlinelibrary.wiley.com
T‐Cell Redirecting Strategies in Large B‐Cell Lymphoma and Follicular Lymphoma
The advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory large B-cell lymphoma (LBCL). After achieving regulatory approval in thi...
021
Francesco Bertoni @frbertoni.bsky.social · 20/06/2025
The results showing the benefit of combining the non-ATP competitive Pi3Kδ inhibitor roginolisib with venetoclax in lymphoid tumors are out in Haematologica. A collaboration of @iorbellinzona.bsky.social, Jennifer Brown’s group and iOnctura colleagues. haematologica.org/newsletter/v...
haematologica.org
Early View | Haematologica
011
Francesco Bertoni @frbertoni.bsky.social · 19/06/2025
A work on new semi-synthetic flavonoid derivatives with anti-tumor activity in lymphoma models is out in eJHaem. Thanks to Eugenio Gaudio, Paulina Biniecka, and Dan Stoicescu for involving us. @iorbellinzona.bsky.social doi.org/10.1002/jha2...
doi.org
Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma Models
Background Despite significant therapeutic progress, many lymphoma subtypes remain difficult to manage due to resistance, relapse, and dose-limiting toxicity. Methods To elucidate the mechanism of...
000
Francesco Bertoni @frbertoni.bsky.social · 19/06/2025
Won Seog Kim's talk on PTCL is about to start. @icmlugano.bsky.social onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com
Peripheral T‐Cell Lymphoma: What's Next?
Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of diseases, with over 30 subtypes according to the International Consensus Classification of Mature Lymphoid Neoplasms (ICC) and W....
000
Reposted by Francesco Bertoni
American Association for Cancer Research (AACR) @theaacr.bsky.social · 18/06/2025
AACR CEO Margaret Foti and #18ICML Organizing Committee Chair Francesco Bertoni co-chaired the AACR-ICML Joint Session on "The Role of Artificial Intelligence in Oncology" today at the International Conference on Malignant Lymphoma in Lugano. @frbertoni.bsky.social @icmlugano.bsky.social ‬
031
Francesco Bertoni @frbertoni.bsky.social · 18/06/2025
Our collaborative work exploring the metabolism-targeting agent KAT/3BP as single and in combination in B-cell lymphoma models is now out in Cancers. Thanks to Chiara Tarantelli, Filippo Spriano, and everybody else who contributed.@iorbellinzona.bsky.social www.mdpi.com/2072-6694/17...
mdpi.com
000
Francesco Bertoni @frbertoni.bsky.social · 18/06/2025
Simone Ferrero's talk on MCL biomarkers at @icmlugano.bsky.social
onlinelibrary.wiley.com
Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
Mantle cell lymphoma (MCL) is a B-cell malignancy characterized by t(11;14)(q13;q32) translocation and heterogeneous clinical behavior. Advances in risk stratification enabled the distinction of conv...
000
Francesco Bertoni @frbertoni.bsky.social · 18/06/2025
Steven Treon's talk on WM at the @icmlugano.bsky.social
onlinelibrary.wiley.com
Diagnosis and Management of Waldenstrom's Macroglobulinemia
You have to enable JavaScript in your browser's settings in order to use the eReader.
000
Francesco Bertoni @frbertoni.bsky.social · 18/06/2025
Sonali Smith's talk now at the @icmlugano.bsky.social @womeninlymphoma.bsky.social
onlinelibrary.wiley.com
Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches
You have to enable JavaScript in your browser's settings in order to use the eReader.
010
Francesco Bertoni @frbertoni.bsky.social · 11/06/2025
“Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL”
cancernetwork.com
Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL
Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.
000
Reposted by Francesco Bertoni
Institute of Oncology Research (IOR) @iorbellinzona.bsky.social · 05/06/2025
#IORjobs Open PhD Position! Join Arianna Baggiolini @ariannabaggiolini.bsky.social ’s Lab to work on human pluripotent stem cell (hPSC)-based models of the peripheral nervous system and disease. Info and application: ior.usi.ch/events-news/...
012
Francesco Bertoni @frbertoni.bsky.social · 04/06/2025
I agree with this rank!
faroutmagazine.co.uk
Every The Clash album ranked from worst to best
We are working our way through the catalogue of The Clash and reflecting on a career charged with authenticity and ranking their albums in order of greatness
000
Francesco Bertoni @frbertoni.bsky.social · 04/06/2025
Airolo-Andermatt in funivia: idea per il futuro
laregione.ch
In funivia da Airolo ad Andermatt, il progetto muove i primi passi
Il gruppo Porta Gottardo vorrebbe collegare le due località attraverso una serie di cabinovie. Mauro Pini: ‘Opportunità di sviluppo per l’Alta Leventina’
010
Francesco Bertoni @frbertoni.bsky.social · 01/06/2025
Sustained Efficacy of Zanubrutinib in Chronic Lymphocytic Leukemia www.onclive.com/view/long-te...
onclive.com
Long-Term Data Underscore Role of Zanubrutinib in Treatment-Naive CLL/SLL With 17p Deletions
Zanubrutinib retained long-term efficacy as a frontline treatment in CLL/SLL harboring 17p deletions.
000
Reposted by Francesco Bertoni
Tatiana Prowell, MD @tmprowell.bsky.social · 30/05/2025
The @ascocancer.bsky.social Ed Book is the highest-quality, peer-reviewed, FREE #oncology #MedEd ever. Whether or not you’re at #ASCO25, don’t miss this resource, #OncSky #MedSky, #MedStudentSky! Drop a 📌 in the comments to bookmark the link for later. ascopubs.org/toc/edbk/cur... #OncoAlert
1236
Reposted by Francesco Bertoni
Arianna Baggiolini @ariannabaggiolini.bsky.social · 29/05/2025
📣 Join us! Were looking for a PhD student to join our lab and work on human pluripotent stem cell (hPSC)-based models of the peripheral nervous system and disease. Come be part of our supportive and dynamic lab family in the beautiful Bellinzona, Southern Switzerland 🇨🇭☀️⛰️ ior.usi.ch/events-news/...
ior.usi.ch
PhD Student at the IOR - Institute of Oncology Research in Bellinzona, Switzerland
The Institute of Oncology Research (IOR) The IOR, affiliated with the Università della Svizzera italiana (USI), is located in a brand-new, high-tech research building that hosts more than 20 differ
0108